

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Schwartz Jonathan David</u> _____ (Last) (First) (Middle) C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE _____ (Street) CRANBURY NJ 08512 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ROCKET PHARMACEUTICALS, INC. [ RCKT ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) See Remarks
	3. Date of Earliest Transaction (Month/Day/Year) 03/30/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year) 04/01/2022		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/30/2022		s <sup>(1)</sup>		10,562	D	\$15.94 <sup>(3)</sup>	213,967	D	
Common Stock	03/30/2022		s <sup>(1)</sup>		34,438	D	\$16.56 <sup>(4)</sup>	179,529	D	
Common Stock	03/31/2022		s <sup>(1)(2)</sup>		9,002	D	\$15.9 <sup>(5)</sup>	170,527	D	
Common Stock	03/31/2022		s <sup>(1)(2)</sup>		35,998	D	\$16.15 <sup>(6)</sup>	134,529	D	
Common Stock	04/01/2022		s <sup>(1)(2)</sup>		12,974	D	\$15.86 <sup>(7)</sup>	121,555	D	
Common Stock	04/01/2022		s <sup>(1)(2)</sup>		32,026	D	\$16.2 <sup>(8)</sup>	89,529	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

**Explanation of Responses:**

- This amendment is being filed to amend and restate the footnote (1) in the original Form 4, filed on April 1, 2022, in its entirety as follows: "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2021, as modified (the "10b5-1 Plan"), under which the reporting person has irrevocably elected to satisfy the tax obligations through these sales and do not represent discretionary trades by the reporting person."
- The original Form 4, filed on April 1, 2022, is being amended by this amendment to include additional transactions that were effected pursuant to the 10b5-1 Plan on March 31, 2022 and April 1, 2022.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$15.87 to \$15.99, inclusive. The reporting person undertakes to provide to Rocket Pharmaceuticals, Inc., any securityholder of Rocket Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5, 6, 7 and 8 to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$16.00 to \$16.95, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$15.83 to \$15.99, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$16.00 to \$16.45, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$15.70 to \$15.99, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$16.00 to \$16.45, inclusive.

**Remarks:**

Chief Medical Officer & Clinical Development, SVP.

/s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz 04/04/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.